Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9468147 | 0.90 | TDP1 (0.33) | TDP1 | |
| SCHEMBL1876097 | 0.89 | BACE1 (0.31) | — | |
| SCHEMBL2142592 | 0.83 | — | — | |
| SCHEMBL21379404 | 0.81 | MAPT (0.31) | — | |
| SCHEMBL28790081 | 0.81 | MAPT (0.31) | — | |
| SCHEMBL1085871 | 0.79 | MAPT (0.33) | TDP1 | |
| SCHEMBL2948345 | 0.79 | KDM4E (0.34) | — | |
| SCHEMBL18595340 | 0.79 | — | — | |
| SCHEMBL9312673 | 0.79 | TDP1 (0.47) | TDP1 | |
| SCHEMBL2163046 | 0.77 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| CN-110831940-B | New substituted azaindoline derivatives as NIK inhibitors | 詹森药业有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-01 | — | — | US | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| EP-3649127-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | Janssen Pharmaceutica NV (BE) | 2020-05-13 | — | — | EP | disclosed |
| CN-110831940-A | Novel substituted azaindoline derivatives as NIK inhibitors | 詹森药业有限公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2019008011-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-10 | — | — | WO | disclosed |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| US-9169277-B2 | Epoxidation catalysts | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20110257415-A1 | EPOXIDATION CATALYSTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-10-20 | — | — | US | disclosed |
| EP-0409412-B1 | Diaryl ether cyclic ethers | ICI PLC (GB) | 1994-07-20 | — | — | EP | disclosed |
| EP-0375457-B1 | Cyclic ether derivatives | ICI PLC (GB) | 1994-03-16 | — | — | EP | disclosed |
| US-5219881-A | Enzyme inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-15 | — | — | US | disclosed |
| US-5137913-A | Inhibitors of the enzyme 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-08-11 | — | — | US | disclosed |
| US-5098932-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC, ICI PHARMA (FR) | 1992-03-24 | — | — | US | disclosed |
| EP-0409412-A2 | Diaryl ether cyclic ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-23 | — | — | EP | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0375368-A2 | Alcohol and ether derivatives | ZENECA LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375457-A2 | Cyclic ether derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | TDP1 1731/4885 |
| US-20110257415-A1 | EPOXIDATION CATALYSTS | PPOX, MPO, CAT | TDP1 2981/4885 |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, MAP3K14 | TDP1 1376/4885 |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | TDP1 2226/4885 |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | TDP1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.